Stock A223250 DREAMCIS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials DreamCIS, Inc.

Equities

A223250

KR7223250002

Healthcare Facilities & Services

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 13/05/2024 BST 		5-day change 1st Jan Change
4,250 KRW +0.71% Intraday chart for DreamCIS, Inc. +10.39% +30.57%
02-22 Curi Bio, Genetox and DreamCIS Sign MOU for Strategic Collaboration on 3D Neuromuscular Junction Model for Botox Potency Assay CI
2023 T&R Biofab Co., Ltd. announced that it has received KRW 1.999996 billion in funding from Korea Investment Partners Co. Ltd., DreamCIS, Inc. CI

Valuation

Fiscal Period: December 2020 2021 2022 2023
Capitalization 1 108,256 73,285 61,653 75,041
Enterprise Value (EV) 1 77,409 44,302 44,094 58,256
P/E ratio 20.3 x 22.6 x 13.8 x 20.7 x
Yield - - - -
Capitalization / Revenue 4.61 x 2.8 x 1.59 x 1.57 x
EV / Revenue 3.3 x 1.69 x 1.13 x 1.22 x
EV / EBITDA 13.5 x 9.58 x 5.77 x 15.6 x
EV / FCF 40.8 x 13.2 x 6.6 x 15.2 x
FCF Yield 2.45% 7.59% 15.2% 6.59%
Price to Book 2.97 x 1.86 x 1.26 x 1.41 x
Nbr of stocks (in thousands) 22,263 22,636 23,048 23,054
Reference price 2 4,862 3,238 2,675 3,255
Announcement Date 12/03/21 11/03/22 22/03/23 15/03/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023
Net sales 1 23,489 26,153 38,874 47,844
EBITDA 1 5,750 4,623 7,635 3,737
EBIT 1 4,794 3,617 5,818 1,588
Operating Margin 20.41% 13.83% 14.97% 3.32%
Earnings before Tax (EBT) 1 4,900 3,945 5,155 4,406
Net income 1 4,854 3,229 4,405 3,739
Net margin 20.66% 12.35% 11.33% 7.81%
EPS 2 239.2 143.0 193.8 157.0
Free Cash Flow 1 1,898 3,364 6,683 3,837
FCF margin 8.08% 12.86% 17.19% 8.02%
FCF Conversion (EBITDA) 33% 72.77% 87.52% 102.68%
FCF Conversion (Net income) 39.1% 104.18% 151.69% 102.63%
Dividend per Share - - - -
Announcement Date 12/03/21 11/03/22 22/03/23 15/03/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023
Net Debt 1 - - - -
Net Cash position 1 30,847 28,983 17,559 16,786
Leverage (Debt/EBITDA) - - - -
Free Cash Flow 1 1,898 3,364 6,683 3,837
ROE (net income / shareholders' equity) 20.6% 8.67% 10.2% 7.19%
ROA (Net income/ Total Assets) 8.14% 4.29% 5.4% 1.19%
Assets 1 59,626 75,204 81,586 313,857
Book Value Per Share 2 1,638 1,739 2,124 2,316
Cash Flow per Share 2 187.0 160.0 388.0 245.0
Capex 1 275 992 591 615
Capex / Sales 1.17% 3.79% 1.52% 1.29%
Announcement Date 12/03/21 11/03/22 22/03/23 15/03/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Medical & Diagnostic Laboratories

1st Jan change Capi.
DREAMCIS, INC. Stock DreamCIS, Inc.
+30.57% 74.46M
SONIC HEALTHCARE LIMITED Stock Sonic Healthcare Limited
-15.71% 8.57B
RADNET, INC. Stock RadNet, Inc.
+67.50% 4.3B
SYNLAB AG Stock SYNLAB AG
-9.28% 2.47B
DR. LAL PATHLABS LIMITED Stock Dr. Lal PathLabs Limited
-2.63% 2.46B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD. Stock Guangzhou Kingmed Diagnostics Group Co., Ltd.
-42.54% 2.31B
NEOGENOMICS, INC. Stock NeoGenomics, Inc.
-6.49% 1.93B
FLEURY S.A. Stock Fleury S.A.
-20.45% 1.53B
DIAN DIAGNOSTICS GROUP CO.,LTD. Stock Dian Diagnostics Group Co.,Ltd.
-41.24% 1.2B
METROPOLIS HEALTHCARE LIMITED Stock Metropolis Healthcare Limited
+10.26% 1.14B
Medical & Diagnostic Laboratories
  1. Stock Market
  2. Equities
  3. A223250 Stock
  4. Financials DreamCIS, Inc.